Dr Ted Witek joins Kuano’s board of directors
Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines is pleased to announce the appointment of Dr Ted Witek to their board of directors. Kuano believes that Dr Witek, with his extensive experience in healthcare, will provide invaluable insight and direction to Kuano.
Dr Witek has decades of experience in research, development, and leadership as well as executive responsibilities as CSO and CEO. He has managed some of the sectors largest strategic alliances. He is currently Professor at the University of Toronto, directing the school’s Doctor of Public Health Program. He brings a breadth of experience to Kuano from his base in North America.
When asked Dr Witek said,
“I am pleased and excited to be joining the board and senior management at such a dynamic time for Kuano. At our doorstep is the establishment of franchises around specific target classes and disease areas, along with the overall scale up of business development”
Dr. Witek served Boehringer Ingelheim Pharmaceuticals for nearly 25 years where he held various pharmacology and clinical research positions, including Director of Respiratory and Immunology Clinical Research leading to his roles as President and CEO of Boehringer Ingelheim’s Canadian and Portuguese operations. He led the Global Operating Team for Spiriva serving as Co-Chair of the Global Alliance with Pfizer.
Dr. Witek also was Chief Scientific Officer & Senior Vice President, Corporate Partnerships, at Innoviva (Formerly Theravance, Inc.). He also served on the Board of Directors of Canada’s Research-Based Pharmaceutical Companies (Rx&D) including Chair of the Health Technology Assessment and Public Relations Committee. He is currently a Professor & Senior Fellow at the University of Toronto’s School of Public Health & Leslie Dan Faculty of Pharmacy. He serves as Director of the DrPH program. Dr. Witek is the author of more than 100 scientific papers as well as several chapters and books.
Dr. Witek holds a Doctor of Public Health from Columbia University and a Master of Public Health from Yale University and an MBA from Henley Management College in the UK.
Kuano, founded in 2020, provides a cutting edge quantum simulation platform which enables scientists to see and model enzymes in their dynamic state, opening new possibilities for more effective drug design. Combining these unique enzyme profiles with its suite of AI tools, Kuano can then predict the best structures with which to target them. Drug candidates designed this way are a precise match to the target enzyme, meaning that they are therefore likely to be more potent with fewer side effects. The platform has already been validated in three separate disease areas, including bowel cancer and lymphoma.
